CCXI stock forecast
Our latest prediction for ChemoCentryx, Inc.'s stock price was made on the Aug. 3, 2020 when the stock price was at 54.73$.
In the short term (2weeks), CCXI's stock price should underperform the market by -2.25%. During that period the price should oscillate between -10.76% and +8.28%.
In the medium term (3months), CCXI's stock price should underperform the market by -6.30%. During that period the price should oscillate between -36.83% and +20.29%.Get email alerts
Create a solid portfolio with CCXI
About ChemoCentryx, Inc.
ChemoCentryx, Inc. is a biopharmaceutical company engages in the development and commercialization of medicines. It focuses on inflammatory disorders, autoimmune diseases, and cancer. Its drug candidates such as Avacopan and CCX140, selectively blocks a specific chemoattractant receptor, leaving the rest of the immune system intact. The company was founded by Thomas J. Schall in 1997 and is headquartered in Mountain View, CA.
At the moment the company generates 33M USD in revenues.
On its last earning announcement, the company reported a loss of -1.10$ per share.
The book value per share is 0.56$
Three months stock forecastAug. 3, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|